PharmaBlock Sciences Nanjing Inc Class A (300725) - Total Assets
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) holds total assets worth CN¥7.79 Billion CNY (≈ $1.14 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 300725 operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
PharmaBlock Sciences Nanjing Inc Class A - Total Assets Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's total assets have evolved over time, based on quarterly financial data. See PharmaBlock Sciences Nanjing Inc Class A shareholders equity for net asset value and shareholders' equity analysis.
PharmaBlock Sciences Nanjing Inc Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmaBlock Sciences Nanjing Inc Class A's total assets of CN¥7.79 Billion consist of 55.1% current assets and 45.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.9% |
| Accounts Receivable | CN¥485.61 Million | 9.8% |
| Inventory | CN¥840.17 Million | 17.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥107.98 Million | 2.2% |
| Goodwill | CN¥355.74 Million | 7.2% |
Asset Composition Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 300725 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaBlock Sciences Nanjing Inc Class A's current assets represent 55.1% of total assets in 2024, a decrease from 65.7% in 2013.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2024, down from 22.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 17.0% of total assets.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Total Assets
Key competitors of PharmaBlock Sciences Nanjing Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
PharmaBlock Sciences Nanjing Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.59 | 3.33 | 3.94 |
| Quick Ratio | 3.43 | 2.21 | 3.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.08 Billion | CN¥1.88 Billion | CN¥1.40 Billion |
PharmaBlock Sciences Nanjing Inc Class A - Advanced Valuation Insights
This section examines the relationship between PharmaBlock Sciences Nanjing Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -3.3% |
| Total Assets | CN¥4.94 Billion |
| Market Capitalization | $1.24 Billion USD |
Valuation Analysis
Below Book Valuation: The market values PharmaBlock Sciences Nanjing Inc Class A's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: PharmaBlock Sciences Nanjing Inc Class A's assets decreased by 3.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below shows the annual total assets of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.94 Billion ≈ $722.19 Million |
-3.31% |
| 2023-12-31 | CN¥5.10 Billion ≈ $746.88 Million |
+4.97% |
| 2022-12-31 | CN¥4.86 Billion ≈ $711.49 Million |
+38.65% |
| 2021-12-31 | CN¥3.51 Billion ≈ $513.17 Million |
+44.60% |
| 2020-12-31 | CN¥2.43 Billion ≈ $354.90 Million |
+135.66% |
| 2019-12-31 | CN¥1.03 Billion ≈ $150.60 Million |
+35.21% |
| 2018-12-31 | CN¥761.16 Million ≈ $111.38 Million |
+34.15% |
| 2017-12-31 | CN¥567.40 Million ≈ $83.03 Million |
+89.67% |
| 2016-12-31 | CN¥299.15 Million ≈ $43.77 Million |
+73.44% |
| 2015-12-31 | CN¥172.48 Million ≈ $25.24 Million |
+69.83% |
| 2014-12-31 | CN¥101.56 Million ≈ $14.86 Million |
+19.30% |
| 2013-12-31 | CN¥85.13 Million ≈ $12.46 Million |
-- |
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more